- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30441
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
回复 lyq2003526 的帖子
This paper may interest you
J Hepatol. 2012 Feb 15.
Source: http://www.ncbi.nlm.nih.gov/pubmed/22343167
HBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis
B patients on lamivudine therapy for over 5 years. Fasano M, Lampertico P,
Marzano A, Di Marco V, Niro GA, Brancaccio G, Marengo A, Scotto G,
Brunetto MR, Gaeta GB, Rizzetto M, Angarano G, Santantonio T. SourceClinic
of Infectious Diseases, University of Bari, Policlinico, Bari, Italy.
Abstract BACKGROUND & AIMS: In long-term responder patients, it is unclear
if lamivudine (LAM) monotherapy should be continued or switched to a
high-genetic-barrier analogue. This study aims at assessing LAM efficacy
over a 5-year period and the residual risk of drug resistance. The rate of
HBsAg clearance and LAM long-term safety profile were also evaluated.
METHODS: 191 patients with chronic HBeAg-negative hepatitis B successfully
treated with LAM monotherapy for at least 5 years were included.
Biochemical and virological tests were assessed every 3 months in all
patients and HBsAg quantification was performed in 45/191.
Reverse-transcriptase (RT) region was directly sequenced in virological
breakthrough patients. RESULTS: 191 patients (148 males, median age 53
years, 72 with compensated cirrhosis) responding to 60-month-LAM
monotherapy continued receiving LAM monotherapy beyond the initial 5 years
and were followed for an additional 36-month median period (range 1-108).
Virological response was maintained in 128/191 patients (67%) and HBsAg
clearance was observed in 15/128 (11.7%) after a 32-month median period
(range 1-65). The 63 remaining patients (33%) showed virological
breakthrough after a 15-month median treatment (range 1-78). RT region
analysis was performed in 38/63 breakthrough patients and LAM resistant
mutations were found in 37/38. No significant side effects were observed.
CONCLUSIONS: In long-term responder patients, continuation of LAM
monotherapy resulted in persistent viral suppression in most cases with
undetectable HBV DNA by real-time PCR; moreover, 11.7% of these patients
cleared HBsAg. Selection of LAM resistance, however, can still occur even
after successful long-term therapy, thus emphasizing the importance of a
careful virological monitoring.
J肝胆病杂志。 2012年二月15日。
资料来源:http://www.ncbi.nlm.nih.gov/pubmed/22343167
HBeAg阴性慢性乙型肝炎HBV DNA抑制和HBsAg清除
乙型肝炎患者拉米夫定治疗5年以上。法萨诺男,Lampertico带够,
马扎诺一邸马可波罗至五,德尼罗遗传,BrancaccioĞ,马伦哥一个,ScottoĞ
brunetto议员,加埃塔GB的,Rizzetto中号,AngaranoĞ,Santantonio吨SourceClinic
传染病,Policlinico,巴里,意大利巴里大学。
摘要背景与目的:在长期的应答患者,目前还不清楚
如果应继续拉米夫定(LAM)单一或切换到
高基因屏障模拟。本研究旨在评估林疗效
超过5年期和耐药性的残余风险。率
HBsAg清除和林的长期安全性进行了评价。
方法:对191例慢性乙肝HBeAg阴性成功
至少5年的林单一治疗都包括在内。
生化和病毒学测试评估每3个月
病人和乙肝表面抗原定量在45/191。
逆转录(RT)区直接测序在病毒学
突破性的患者。结果:191例(148位男性,平均年龄53
多年来,代偿性肝硬化72)60个月的林
单一继续接受超出了最初的5年,林单一
和一个额外的36个月的中位数时间(范围1-108)随访。
病毒学应答维持在128/191例(67%)和HBsAg
在15/128(11.7%)后32个月的中位数期间的间隙观察
(范围1-65)。 63(33%),其余患者表明病毒学
突破后15个月的平均治疗(1-78)。 RT区
突破38/63患者进行分析和林耐
37/38的基因突变被发现。没有明显的副作用进行观察。
结论:在长期的应答患者,林延续
在大多数情况下,单一,导致在持续抑制病毒
实时PCR检测不到HBV DNA的,而且这些患者中,11.7%
清除乙肝表面抗原。林耐的选择,但是,仍时有发生,甚至
成功后的长期治疗,从而强调了重要性
小心病毒学监测。
|
|